Research Reports

Indegene Shares

Indegene company logo

Indegene

PHYSICAL

PUBLIC LIMITED

Price Chart

1W
1M
1Y
MAX

High

-

Low

-

Return

-

No data available

Indegene Essentials

As of April 16, 2026, Indegene, Listed Shares are trading at ₹496.00 per share.

Face Value

info icon

2

Total Shares

info icon

22,14,75,114

Market Cap

info icon

10,985.17 Cr

Sector

info icon

Information Technology

Sub-sector

info icon

Health Tech

Category

info icon

Listed

About Indegene

  • Indegene Limited offers research and development and management services to healthcare and pharmaceuticals enterprises. It is leveraging over two decades of expertise in the life sciences domain and employing purpose-built technology, a leading "digital-first" commercialization company that exclusively serves the global life sciences industry.
  • Their comprehensive solutions empower biopharmaceutical, emerging biotech, and medical device companies to develop, launch, and drive product sales throughout their lifecycle in a more effective, efficient, and modern manner. The company's portfolio encompasses solutions for all facets of commercial, medical, regulatory, and R&D operations within the life sciences sector.
  • The company offers Enterprise Commercial Solutions, primarily assisting life sciences companies with their digital marketing needs. This aligns with market trends, as sales and marketing formed the largest expenditure segment for life sciences companies in 2021 (Everest Report). Providers like this company aid clients by crafting tailored marketing plans and campaigns, including the generation of promotional content based on approved clinical trial data (Everest Report).
  • These solutions are designed to drive scalable efficiency for life sciences companies. Emphasis is placed on personalized engagement strategies for healthcare professionals (HCPs) and patients, leveraging technology and analytics.
  • Additional offerings include digital asset management, marketing automation, customer data management, and analytics solutions, enabling campaign effectiveness measurement.
  • Moreover, the company's proprietary Natural Language Processing (NLP)-based tools and platforms within these solutions aim to reduce reliance on manpower, enhance efficiency, and ensure regulatory compliance.
  • The company boasts an impressive client roster, including 19 of the 20 largest biopharmaceutical companies in the world by 2021 revenue (as verified by the Everest Report). This translates to over 70% of the company's total revenue from continuing operations consistently stemming from these top 19 clients across 2022, 2021, and 2020. As of June 30, 2022, the company maintains a total of 52 active clients, defined as those generating at least $0.25 million in revenue over the preceding year. Within this group, 21 contribute revenues between $1 million and $10 million, while three fall within the $10 million to $25 million range, and four generate over $25 million each.
  • The company known as Indegene Limited was originally incorporated as ‘Indegene Lifesystems Private Limited’ in Ahmedabad, Gujarat. This private limited company was established under the provisions of the Companies Act, 1956, and received its certificate of incorporation on October 16, 1998, issued by the Registrar of Companies in Gujarat, Dadra & Nagar Haveli at Ahmedabad. Later, the company’s registered office was relocated from Maharashtra to Karnataka in February 2017. As part of this transition, the company’s name was updated to ‘Indegene Limited’, and a fresh certificate of incorporation was issued by the Registrar of Companies on November 17, 2022.

Want to See a Detailed Investment Analysis?

Explore in-depth financial analysis, performance metrics, and key disclosures.

Indegene Media

News

Articles

Videos

HFS Research recognizes Indegene as a Market Leader in the HFS Horizons: Life Sciences Service Providers, 2023 report

HFS Research recognizes Indegene as a Market Leader in the HFS Horizons: Life Sciences Service Providers, 2023 report

24 Nov 2023

https://finance.yahoo.com/news

Indegene prepares for ₹ 2500 cr IPO

Indegene prepares for ₹ 2500 cr IPO

14 Sep 2023

https://www.livemint.com/

Indegene gets Sebi nod to float IPO

Indegene gets Sebi nod to float IPO

03 Aug 2023

https://economictimes.indiatimes.com/

Frequently Asked Question (FAQs)

Where can I find the annual report of Indegene Ltd?

The annual report of Indegene Ltd is available in the annual report section.

How to buy Indegene Listed Shares?

Please find below the procedure for buying Indegene Listed Shares at Planify.
• 1. You confirm booking of Indegene Listed Shares with us at a trading price.
• 2. You provide your client master report (ask the broker if not available) along with PAN Card and Cancelled Cheque in case you are not transferring funds from the bank account as mentioned in the CMR Copy. These are KYC documents required as per SEBI regulations.
• 3. We will provide the bank details.
• 4. You need to transfer funds in that account.
• 5. Payment has to be done in RTGS/NEFT/IMPS CHEQUE TRANSFER. No CASH DEPOSIT.
• 6. Payment has to be done from the same account in which shares are to be credited.
• 7. We will transfer the shares in 24 hours if funds are credited before 2 pm.
Important Note: Please note that the lock-in period for selling Indegene Listed Shares is 6 months after listing. Hence you can’t sell Indegene Listed Shares which you bought in Pre-IPO for 6 months after its listing. i.e. You can sell it only after 6 months calculated from the listing date.

What is the lock-in period of Indegene Listed Shares?

Lock-in period of Indegene Listed Shares depends upon category of investors.
• 1. Venture Capital Funds or Alternate Investment Fund of Category -I or II, or Foreign Venture Capital Investor - lock-in Period of 6 months from the date of acquisition of Indegene Listed Shares.
• 2. Other Investors (include Retail, HNIs or Body Corporate) lock-in Period of 6 months from the date of listing of IPO of Indegene Listed Shares.
This new SEBI rule was introduced in the month of August-2021, wherein the SEBI has reduced the lock-in period previously from 1 year to 6 months to encourage more and more funds to be invested in startups which are going to public or IPO in near future. Reduction of lock-in is seen as big step and after that many PMS funds are advising their clients to invest in Pre-IPO shares to get the benefit of early stage investment.

See More

Indegene

₹ 496

cartIcon